$2.00
-0.03 (-1.48%)
Open$2.02
Previous Close$2.03
Day High$2.05
Day Low$1.94
52W High$2.60
52W Low$1.09
Volume—
Avg Volume430.9K
Market Cap56.34M
P/E Ratio—
EPS$-0.69
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+743.5% upside
Current
$2.00
$2.00
Target
$16.87
$16.87
$11.09
$16.87 avg
$25.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 56.3K | 109.8K | 11.20M |
| Net Income | -52,263,981 | -91,655,461 | 1.78M |
| Profit Margin | -91,866.0% | -87,272.7% | 15.9% |
| EBITDA | -53,818,971 | -99,625,920 | 2.32M |
| Free Cash Flow | — | — | 977.1K |
| Rev Growth | -48.7% | -48.7% | +3.1% |
| Debt/Equity | — | — | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |